Comparative Pharmacology
Head-to-head clinical analysis: LASTACAFT versus NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LASTACAFT versus NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE.
LASTACAFT vs NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective histamine H1 receptor antagonist; inhibits mast cell degranulation and reduces release of inflammatory mediators.
Naphazoline is an alpha-adrenergic receptor agonist that causes vasoconstriction of conjunctival blood vessels, reducing redness and edema. Pheniramine is a histamine H1-receptor antagonist that blocks the effects of histamine, reducing itching and allergic symptoms.
1 drop in each affected eye twice daily (approximately every 8 hours)
1-2 drops or sprays in each nostril every 4-6 hours as needed, not to exceed 5-7 days
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours; clinically, dosing is twice daily.
Naphazoline: Terminal elimination half-life approximately 2-3 hours; clinical effects may persist longer due to local vasoconstriction. Pheniramine: Terminal elimination half-life approximately 14-16 hours; appropriate for twice-daily dosing.
Renal: approximately 70% as unchanged drug; fecal: approximately 30% as metabolites.
Naphazoline: Renal excretion of unchanged drug and metabolites accounts for >80% of elimination. Pheniramine: Renal excretion of unchanged drug and metabolites accounts for >90% of elimination, with <5% biliary/fecal elimination.
Category C
Category C
Ophthalmic Antihistamine
Ophthalmic Antihistamine/Decongestant